Inzy stock forecast
Nov 14, 2023 · Inozyme Pharma Stock Forecast and Price Target. The average price target for Inozyme Pharma's stock set by recognized analysts recently is $23.00, which would result in a potential upside of approximately 701.39% if it reached this mark. The estimation is based on a high estimate of $40.00 and a low estimate of $5.00. 16 analysts have issued twelve-month price objectives for Alibaba Group's shares. Their BABA share price targets range from $90.00 to $150.00. On average, they expect the company's share price to reach $129.20 in the next year. This suggests a possible upside of 74.6% from the stock's current price.
Did you know?
INCY Earnings Date and Information. Incyte last announced its earnings results on October 31st, 2023. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.91. The company earned $919.03 million during the quarter, compared to the consensus estimate of …Earnings for Incyte are expected to grow by 28.00% in the coming year, from $3.00 to $3.84 per share. Incyte has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 6th, 2024 based off prior year's report dates. Read More.For Sorrento Therapeutics stock forecast for 2023, 8 predictions are offered for each month of 2023 with average Sorrento Therapeutics stock forecast of $0.76, a high forecast of $1.2, and a low forecast of $0.36. The average Sorrento Therapeutics stock forecast 2023 represents a 127.59% increase from the last price of $0.332199990749359.Inozyme Pharma Inc. 3.23. Delayed Data. As of Nov 16. +0.03 / +0.94%. Today’s Change. 0.99. Today ||| 52-Week Range. 7.33. Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ...Incyte Corp Revenue Forecast for 2023 - 2025 - 2030. Incyte Corp's Revenue has seen impressive growth In the last three years, rising from $2.16B to $3.39B – a growth of 57.25%. In the next year, analysts believe that Revenue will reach $3.93B – an increase of 15.71%. For the next eight years, the forecast is for Revenue to grow by 16.18%.Nasdaq Futures -44.75(-0.28%) Russell 2000 Futures 1,798.80 -12.20(-0.67%) Crude Oil 74.30 -1.24(-1.64%) Gold 2,013.20 +10.20(+0.51%) Inozyme Pharma, Inc. (INZY) NasdaqGS - NasdaqGS Real Time...Nov 20, 2023 · Target values for the price of one Incyte share for Jan 2025. The weighted average target price per Incyte share in Jan 2025 is: 59.50. In Jan, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 7.054% volatility is expected. Pessimistic target level: 56.44. Optimistic target level: 60.73. Forecasts are adjusted once a day taking into account the price change of the previous day. To date, analysts have a $83.06 target price for Incyte stock stock. Today 200 Day Moving Average is the resistance level (70.22 $). 50 Day Moving Average is the resistance level (63.33 $). 2023.See Inozyme Pharma, Inc. (INZY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Find the latest Cano Health, Inc. (CANO) stock quote, history, news and other vital information to help you with your stock trading and investing.See Full INZY Report. INZY stock closed at $4.37 and is up $0.21 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. INZY has a strong overall score of 92 meaning the stock holds a better value than 92% of stocks at its current price.Find the latest Fangdd Network Group Ltd. (DUO) stock quote, history, news and other vital information to help you with your stock trading and investing.For Sorrento Therapeutics stock forecast for 2023, 8 predictions are offered for each month of 2023 with average Sorrento Therapeutics stock forecast of $0.76, a high forecast of $1.2, and a low forecast of $0.36. The average Sorrento Therapeutics stock forecast 2023 represents a 127.59% increase from the last price of $0.332199990749359. President exercised options and sold US$65k worth of stock Jun 26. Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application …Incyte Corp. Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib).SEMR | Complete SEMrush Holdings Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.American Electric Power. Cramer said that he likes the stock because the company is well-run, and utility stocks tend to perform well during economic slowdowns. Dollar Tree. While he does like the ...Find the latest MEI Pharma, Inc. (MEIP) stock quote, history, news and other vital information to help you with your stock trading and investing.Aug 29, 2023 · Find the latest Incyte Corporation (INCY) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.com
Find the latest Moleculin Biotech, Inc. (MBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Inozyme Pharma Inc. 3.23. Delayed Data. As of Nov 16. +0.03 / +0.94%. Today’s Change. 0.99. Today ||| 52-Week Range. 7.33. Being prepared to weather a hurricane — whether that involves fortifying your home or creating an emergency evacuation plan — is an important part of making it through the storm. Hurricanes travel across the ocean via massive, circular gust...Nov 20, 2023 · Target values for the price of one Incyte share for Jan 2025. The weighted average target price per Incyte share in Jan 2025 is: 59.50. In Jan, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 7.054% volatility is expected. Pessimistic target level: 56.44. Optimistic target level: 60.73.
Find the latest Cano Health, Inc. (CANO) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Cabaletta Bio, Inc. (CABA) stock quote, history, news and other vital information to help you with your stock trading and investing.Sep 27, 2023 · INZY stock had a strong performance on September 27, 2023, based on the information provided by CNN Money. The 12-month price forecasts from 6 analysts for Inozyme Pharma Inc have a median target of $16.00, with a high estimate of $40.00 and a low estimate of $15.00. …
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. INZY Stock 12 Months Forecast. $16.00. (315.58% Upside) Based on 3 . Possible cause: Find the latest VYNE Therapeutics Inc. (VYNE) stock quote, history, news a.
See Inozyme Pharma, Inc. (INZY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Inozyme Pharma Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction. ... INZY Related stocks. Symbol 3M %Chg ; INZY -36.16% : Inozyme Pharma Inc: AMGN +3 ...
INZY has a market cap of $257mn and a cash balance of $148mn. R&D expenses were $47.8 million for the year ended December 31, 2022, while G&A expenses were $20.8 million. At that rate, they have …Nasdaq Futures -44.75(-0.28%) Russell 2000 Futures 1,798.80 -12.20(-0.67%) Crude Oil 74.30 -1.24(-1.64%) Gold 2,013.20 +10.20(+0.51%) Inozyme Pharma, Inc. (INZY) NasdaqGS - NasdaqGS Real Time... Analyzing the anticipated performance of Incyte, the ceiling value that the stock is expected to reach in 2025 stands at a promising $79.7.Indicating a bullish trend, an upside potential of 40.27% signals profitable prospects, with an average monthly return of 1.55%, beckoning investors to consider amplifying their portfolios.
View the latest Incyte Corp. (INCY) stock price, news, hist Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Inozyme Pharma Inc have a median target of 16.00, with a high estimate of 40.00 and a low estimate of 15.00. The median ...Deutsche Bank has become the latest big name on Wall Street to issue a bullish stock-market forecast for 2024, with analysts predicting the S&P 500 will soar to … The predictions for the future INCY stock price range from a lFind the latest Incyte Corporation (INCY) stock forecast Incyte Stock (NASDAQ:INCY), Analyst Ratings, Price Targets, Predictions. Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if ...Overview Stock Screener Earnings Calendar Sectors Nasdaq | INZY U.S.: Nasdaq Inozyme Pharma Inc. Watch list NEW Set a price target alert Open Last Updated: Oct 12, 2023 … Inozyme Pharma (INZY) Stock Forecast and Dec 1, 2023 · 16 analysts have issued twelve-month price objectives for Alibaba Group's shares. Their BABA share price targets range from $90.00 to $150.00. On average, they expect the company's share price to reach $129.20 in the next year. This suggests a possible upside of 74.6% from the stock's current price. Stock analysis for Inozyme Pharma Inc (INZY:NASDAQ GS) including stocWebsite. 2015. 56. Doug Treco. https://www.inozyme.com. Inozyme PhUpgrade to Premium to see how . INZY scored acr Find the latest Moleculin Biotech, Inc. (MBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Cenntro Electric Group Limited (CENN) stock quote, history, news and other vital information to help you with your stock trading and investing. Market cap is calculated by taking a company's price per s The high estimate for the stock price was $93.00, while the low estimate was $58.00. This indicates a potential increase of 32.98% from the last recorded price of $53.39. The consensus among 23 polled investment analysts is to hold the stock in Incyte Corp. This rating has remained steady since November, when it was downgraded from a buy rating. See Full INZY Report. INZY stock closed at $4.37 and i[Planning a trip can be an exciting but challenging task.Incyte has risen higher in 16 of those 30 years ov View the latest Incyte Corp. (INCY) stock price, news, historical charts, analyst ratings and financial information from WSJ.Dec 1, 2023 · Analyst Forecast According to 16 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $79.25, which is an increase of 46.71% from the latest price.